Quadruple Thera py of Behcet's Disease.
- Author:
Hyuck Woo SON
1
;
Ju Hwa LEE
;
Myung Jin JOO
Author Information
1. Department of Ophthalmology, Sanggye paik Hospital, The Inje University Medical College, Korea.
- Publication Type:Original Article
- Keywords:
Azathioprine;
Behcet's disease;
Colchicines;
Corticosteroids;
Cyclosporine
- MeSH:
Adrenal Cortex Hormones;
Azathioprine;
Cyclosporine;
Humans;
Inflammation;
Retrospective Studies;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2000;41(10):2220-2225
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Behcet's disease is a multisystematic inflammatory disorder affecting eyes. Visual loss is the most serious effect of Behcet's disease with posterior segment involvement.Because of the disorder's devastating visual consequences, its treatment has received considerable attention.Since the treatment of Behcet's disease has often been unsatisfactory, many different types of treatment have been attempted. We retrospectively reviewed the charts of 28 patients with severe ocular Behcet's disease involving posterior segment.The patients with posterior segment involvement were initially treated with triple regimen (corticosteroid, colchicines, and azathioprine).If intraocular inflammation does not resolve or the inflammatory process recurs, combination with low doses of cyclosporine should be considered (quadruple therapy).Over the course of therapy, visual acuity improved in 25 of 51 eyes (49.01%), remained stable in 14 of 51 eyes (27.45%), and declined in 12 of 51 eyes (23.52%).It improved or maintained the visual acuity in 39 of 51 eyes.There were no serious side effects attributable to triple or quadruple therapy that required withdrawal. The use of corticosteroids, colchicines, azathioprine, and cyclosporine may improve therapeutic efficacy and limit the adverse drug effects, and this combination method appears to be an effective treatment for the ocular complications of Behcet's disease.
